Rezolute, Inc. Annual report pursuant to section 13 and 15(d)

Annual report pursuant to section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2013

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

AntriaBio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. Due to the small number of option holders and all options being to officers and/or directors, AntriaBio has estimated a forfeiture rate of zero. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk- free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. AntriaBio has computed the fair value of all options granted during the year ended June 30, 2013 using the following assumptions:

Expected volatility	106% - 111	%
Risk free interest rate	0.88% - 1.05	%
Expected term (years)	5
Dividend yield	0	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity is as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Options		Exercise Price		Contractual Life
Outstanding, June 30, 2012		-	$	-		-
Granted		9,050,000	$	0.75
Outstanding, June 30, 2013		9,050,000	$	0.75		4.6

Exercisable at June 30, 2013		6,213,890	$	0.75		4.6

Schedule Of Warrants Issued To Agents Activity [Table Text Block]

AntriaBio issued warrants to agents in conjunction with the closing of its convertible notes payable as follows:

			Weighted		Weighted Average
	Number of		Average		Remaining
	Warrants		Exercise Price		Contractual Life
Outstanding, June 30, 2012		-	$	-		-
Warrants issued to placement agents		248,542	$	0.33
Warrants issued to placement agent		1,400,000	$	-
Warrants issued to placement agent		110,000	$	0.85
Outstanding, June 30, 2013		1,758,542	$	0.31		4.1

Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

Significant assumptions were as follows:

Expected volatility	104% - 111	%
Risk free interest rate	0.88% - 1.41	%
Expected term (years)	4.1 - 5
Dividend yield	0	%